This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dendreon Receives FDA Approval for Provenge

SEATTLE ( TheStreet) -- Dendreon (DNDN) has received full approval for its prostate cancer "vaccine" Provenge from the U.S. Food and Drug Administration, the agency said Thursday.

Dendreon shares closed Thursday up 26% to $50.18. The stock was halted for a time at $45.50 soon after the announcement hit the tape.

Provenge becomes the first cancer drug approved that works by activating a patient's own immune system to fight the disease. Under the FDA approval, Dendreon will market Provenge as a treatment for men with advanced prostate cancer that has grown resistant to standard hormone treatment.

"The FDA approval of Provenge is a testament to the courage of the patients and researchers who participated in our studies and is the culmination of nearly 15 years of research and development by our dedicated employees," said Dendreon CEO Mitch Gold, in a statement.

Provenge was approved based on a pivotal study in 512 men demonstrating that treatment with Provenge could extend survival by 4.1 months compared to patients not treated with Provenge.

"The availability of Provenge provides a new treatment option for men with advanced prostate cancer, who currently have limited effective therapies available,” said Dr. Karen Midthun, acting director of the FDA's Center for Biologics Evaluation and Research, in a statement.

Dendreon's struggles to bring Provenge to market have been long documented. An FDA advisory panel in 2007 recommended Provenge's approval but the FDA later decided to request more clinical data. Dendreon then ran another clinical trial that produced positive results in April 2009 and allowed the company to refile Provenge with FDA.

Dendreon is expected to treat its first prostate cancer patient with Provenge in the nect week. The company announced a Provenge treatment price of $93,000, well above Street estimates. Analysts have estimated the drug could generate $1 billion or more in U.S. sales, but that forecast may rise now given the higher Provenge sales price.

The commercial launch of Provenge will be closely watched because the drug is no ordinary off-the-shelf cancer drug. Instead, Provenge is personalized for each individual prostate cancer patient. This adds a logistical complexity to the manufacture and delivery of Provenge that could cause Dendreon some problems, or at least some sleepless nights, in the first days and weeks of the drug's launch. Wall Street will be watching the Provenge launch closely.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
DNDN $0.06 -6.02%
AAPL $95.03 -2.90%
FB $116.73 7.20%
GOOG $691.02 -2.10%
TSLA $247.54 -1.60%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs